GLS GLS

Gelesis Stock Price

5.00
0.30 (6.38%)
Upgrade to Real-Time
Afterhours (Closed)
5.00
Volume 119,436
Bid Price
Ask Price
News -
Day High 5.18

Low
2.55

52 Week Range

High
8.24

Day Low 4.77
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Gelesis Holdings Inc GLS NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.30 6.38% 5.00 17:21:48
Open Price Low Price High Price Close Price Prev Close
4.80 4.77 5.18 5.00 4.70
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,154 119,436 $ 4.99 $ 595,841 - 2.55 - 8.24
Last Trade Time Type Quantity Stock Price Currency
19:00:00 2,055 $ 5.00 USD

Period:

Draw Mode:

Gelesis Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 361.95M 72.39M 19.42M $ 11.19M $ - -2.60 -1.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 9.83k 0.90%

more financials information »

Gelesis News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GLS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.085.324.214.6683,066-0.08-1.57%
1 Month4.985.674.194.7992,3080.020.4%
3 Months2.726.252.553.75362,8362.2883.82%
6 Months7.368.242.553.93310,353-2.36-32.07%
1 Year7.368.242.553.93310,353-2.36-32.07%
3 Years7.368.242.553.93310,353-2.36-32.07%
5 Years7.368.242.553.93310,353-2.36-32.07%

Gelesis Description

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Your Recent History
NYSE
GLS
Gelesis
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220516 06:09:38